Evaluation Optimizing Outcomes in IBD: The Role of Therapeutic Drug Monitoring and Precision Medicine Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Evaluate the prevalence and mechanisms of nonresponse/loss of response associated with biologic therapy 5 4 3 2 1 Assess the latest evidence associated with reactive and proactive TDM with regard to utility, appropriateness of initiation, and treatment adjustments based on trough levels 5 4 3 2 1 Implement optimal strategies and guideline recommendations for TDM, where appropriate, in the management of IBD 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Adam S. Cheifetz, MD 5 4 3 2 1 Raymond K Cross, MD, MS, AGAF, FACG 5 4 3 2 1 Marla Dubinsky, MD 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients do you encounter with IBD on a weekly basis? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No Approximately _____ of patients discontinue anti-TNF therapy for primary non-response. 20%-30% 30%-40% 40%-50% 50%-60% The method of __________ offers objective data to expedite therapy adjustments for individual IBD patients and has demonstrated efficacy in maintaining clinical remission. Enzyme-linked immunosorbent assay analysis of anti-drug antibodies Homogenous mobility shift assay analysis of serum drug concentrations Precision-guided dosing (Bayesian forecasting) Radioimmunoassay analysis of plasma drug concentrations Which of the following is a 2021 expert-recommended use of TDM? Proactive TDM is recommended for individuals with IBD on anti-TNFa therapy Proactive TDM is recommended for individuals with IBD on any biologic therapy Reactive TDM is recommended for individuals with IBD on anti-TNFa therapy Reactive TDM is recommended for individuals with IBD on any biologic therapy How confident are you now in your ability to implement novel tools for TDM in your clinical practice? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Evaluate the mechanism and burden of primary and secondary loss of response on IBD patient outcomes Assess drug trough levels and anti-drug antibodies when determining optimal biologic treatment and dosing strategies Consider the utility of reactive and proactive TDM based on guideline recommendations and real-world evidence Assess the latest data on novel TDM strategies and their implications for IBD treatment Implement precision-guided dosing software where appropriate to inform IBD treatment decisions Other, please specify: Previous